HCW Biologics IncNASDAQ:HCWB
- LAST PRICE1.3650
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2300/ 4
- Ask / Lots1.7700/ 5
- Open / Previous Close0.0000 / 1.3650
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HCWB |
|---|---|---|
| 09:32 ET | 198 | 1.47 |
| 09:34 ET | 1440 | 1.4769 |
| 10:17 ET | 250 | 1.4599 |
| 10:39 ET | 150 | 1.35 |
| 02:11 ET | 387 | 1.306 |
| 02:15 ET | 2451 | 1.3011 |
| 03:00 ET | 200 | 1.3003 |
| 03:05 ET | 500 | 1.3615 |
| 03:43 ET | 100 | 1.365 |
| 03:50 ET | 100 | 1.365 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HCW Biologics Inc | 49.0M | -3.9x | --- |
Genprex Inc | 48.8M | -2.0x | --- |
AVROBIO Inc | 48.5M | -0.5x | --- |
Lantern Pharma Inc | 49.7M | -3.5x | --- |
Magenta Therapeutics Inc | 47.9M | -0.6x | --- |
Bioxytran Inc | 50.6M | -16.9x | --- |
Company Information
HCW Biologics Inc. is a biopharmaceutical company. It focuses on discovering and developing immunotherapies designed to improve health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company uses its TOBI (Tissue factOr-Based fusIon) discovery platform to generate designer, multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the senescence-associated secretory phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9218 is in a clinical trial in patients with advanced pancreatic cancer. HCW9302 is designed to activate and expand regulatory T (Treg) cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors.
Contact Information
- Headquarters
- 2929 N Commerce Pkwy, Miramar, Fl 33025MIRAMAR, FL, United States 33025
- Phone
- 954-842-2024
- Fax
- 954-842-2037
Executives
- Independent Chairman of the Board
- Scott Garrett
- Chief Executive Officer, Founder, Director
- Hing Wong
- Chief Financial Officer
- Rebecca Byam
- Senior Vice President of Business Development
- Lee Flowers
- Chief Scientific Officer, Vice President of Clinical Operations
- Peter Rhode
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $49.0M |
|---|---|
Revenue (TTM) | $5.4M |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.35 |
Book Value | $1.43 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 9.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -232.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
